COVID-19疫苗接种对突破性感染后医疗支出和住院时长的年龄特异性影响:疫苗有效性、网络与普遍安全性(VENUS)研究
该回顾性研究利用日本三个市町村的医疗索赔、接种记录和COVID-19相关信息,分析Delta变异株流行期间618例20-64岁和208例≥65岁突破性感染病例。调整性别、合并症和市町村后,接种疫苗与总医疗支出和住院时长降低相关,且对老年人的效果更明显。
要点
- 20-64岁组接种疫苗后总医疗支出RR为0.53(95%CI 0.44-0.64),≥65岁组为0.51(95%CI 0.39-0.66)。
- 20-64岁组接种疫苗后住院时长RR为0.59(95%CI 0.42-0.83),≥65岁组为0.69(95%CI 0.49-0.98)。
- 接种疫苗与突破性感染后总医疗支出和住院时长降低相关,对老年人的效果更明显。
核心结论
- COVID-19疫苗接种与突破性感染后总医疗支出和住院时长降低相关,对老年人的效果更明显。
研究设计与样本
- 回顾性研究,使用医疗索赔数据、接种记录和COVID-19相关信息,纳入日本三个市町村的COVID-19病例,分为20-64岁和≥65岁两组。
- 采用广义估计方程构建线性回归模型,计算疫苗接种对总医疗支出和住院时长的风险比(RR)及95%置信区间(CI),并调整性别、合并症和市町村。
- 分析618例20-64岁病例(平均年龄38.4岁,女性45.1%)和208例≥65岁病例(平均年龄76.4岁,女性53.8%)。
主要发现
- 20-64岁组接种疫苗对总医疗支出的RR为0.53(95%CI 0.44-0.64),≥65岁组为0.51(95%CI 0.39-0.66)。
- 20-64岁组接种疫苗对住院时长的RR为0.59(95%CI 0.42-0.83),≥65岁组为0.69(95%CI 0.49-0.98)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Although COVID-19 no longer constitutes a Public Health Emergency of International Concern, vaccination remains an important tool for reducing disease burden and mitigating future outbreaks. However, little is known about the impact of vaccination on medical expenditures and hospitalization duration after breakthrough infection. This study aimed to examine this impact during the Delta wave in Japan. METHODS: This retrospective study was conducted using medical care claims data, vaccination records, and COVID-19-related information. COVID-19 cases in three municipalities were categorized into two age groups: 20-64 years and ≥65 years. For each group, we constructed linear regression models with a generalized estimating equation. We calculated the risk ratios (RRs) and 95% confidence intervals (CIs) of COVID-19 vaccination for total medical expenditures and hospitalization duration after adjusting for sex, comorbidities, and municipality. RESULTS: We analyzed 618 cases aged 20-64 years (mean age: 38.4 years, women: 45.1%) and 208 cases aged ≥65 years (76.4 years, 53.8%). The RRs (95% CIs) of vaccination for total medical expenditures were 0.53 (0.44-0.64) in the 20-64 years age group and 0.51 (0.39-0.66) in the ≥65 years age group. Next, the RRs (95% CIs) of vaccination for hospitalization duration were 0.59 (0.42-0.83) in the 20-64 years age group and 0.69 (0.49-0.98) in the ≥65 years age group. CONCLUSIONS: COVID-19 vaccination was associated with lower total medical expenditures and hospitalization duration after breakthrough infection, with a more pronounced effect in older persons.
引用
- Maeda M, Murata F, Fukuda H, et al. The age-specific impact of COVID-19 vaccination on medical expenditures and hospitalization duration after breakthrough infection: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study. Vaccine. 2024. PMID: 38320932. doi:10.1016/j.vaccine.2024.01.082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。